AG
RPRX icon

Artal Group’s Royalty Pharma RPRX Stock Holding History

Artal Group’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-250,000
Closed -$10.5M – 152
2020
Q3 		$10.5M Sell
250,000
-500,000
-67% -$21.5M 0.26% 76
2020
Q2 		$36.4M Buy
+750,000
New +$37.1M 1.02% 25

Other funds holding RPRX

RWJF
Robert Wood Johnson Foundation Princeton, New Jersey $81M AUM 0.47% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
VCG
Vantage Consulting Group Virginia Beach, Virginia $19.7M AUM 280.87% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
HMC
Harvard Management Company Boston, Massachusetts $4.26B AUM 5.81% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SGA
Siguler Guff Advisers New York $56.1M AUM 46.63% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Artal Group's RPRX Position: Q4 2020 in Review

Artal Group sold out of Royalty Pharma (RPRX) in Q4 2020, closing a stake of 250,000 shares — an estimated $10.5M sold.

Artal Group first reported a position in RPRX in Q2 2020 and held it in 2 quarters. The position peaked at $36.4M in Q2 2020. 199 funds tracked by Wall St. Rank hold RPRX as of Q4 2020.

  • Artal Group reported no remaining Royalty Pharma position as of Q4 2020 after selling out during the quarter.
  • Artal Group sold 250,000 Royalty Pharma shares in Q4 2020, an estimated $10.5M.
  • Artal Group first reported a position in Royalty Pharma in Q2 2020 and held it in 2 quarters.
  • Artal Group's Royalty Pharma position peaked at $36.4M in Q2 2020.
  • 199 funds tracked by Wall St. Rank held Royalty Pharma as of Q4 2020.

Based on Artal Group's 13F filing for Q4 2020, filed 11 Feb 2021.